Pharmacoeconomic scenario ofhypolipidemic drugs in the indian market

Hyperlipidemia cardiovascular events and requiring lifelong therapy. Hence the cost of medication plays an important in patient care arising the need for all physicians to keep oneself update price variation of various brands of hypolipidemic drugs. Objective: To analyze the cost variation of hypolipidemic drugs in Indian market Hypolipidemic drugs manufactured by dif tripeli (Indian Drug Review) drug compendium 2017. The difference in the minimum and maximum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per preparation) which were manufactured by different companies were analyzed .In single drug therapy atorvastatin 20 mg has maximum percentage (1017.78%) variation while pravast minimum percentage variation (1.01%). Among lipoprotein lipase activators Finofibrate 200mg showed maximum variation (549.43%) and Bezafibrate 200 mg has least percentage variation (10%). Conclusion: hypolipidemic drugs of same strength and dosage forms. Therefore, physicians should be encouraged to prescribe the drugs by generic names as they are cheaper and in no way inferior to costlier branded counterpart.